+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advances and Challenges on Management of Gastrointestinal Stromal Tumors



Advances and Challenges on Management of Gastrointestinal Stromal Tumors



Frontiers in Oncology 8: 135



Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed cases in the United States. The discovery of activated KIT and PDGFRA mutations and introduction of imatinib revolutionized the treatment strategy and opened up the new era of target therapy for solid tumors. Although surgery remains the primary modality of treatment for curative purpose, almost half of the patients experienced disease recurrence. Tailoring (neo)-adjuvant treatment with imatinib is ongoing to meet the need for an effective therapy. Currently, two drugs (sunitinib and regorafenib) have obtained Food and Drug Administration approval for GISTs after imatinib failure. However, most of the patients eventually progress due to primary or secondary resistance. Deeper understanding of the molecular mechanisms will guide us to develop personalized strategies in the future. Discussion in this review includes current standard management and the most recent advances and multiple ongoing clinical trials with different approaches. This review will provide further steps to be taken to conquer refractory disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045304328

Download citation: RISBibTeXText

PMID: 29868467

DOI: 10.3389/fonc.2018.00135


Related references

Recent advances in the management of gastrointestinal stromal tumors. F1000 Medicine Reports 2, 2010

Recent advances in the management of gastrointestinal stromal tumors. Current Oncology Reports 5(4): 288-294, 2003

Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location. Intractable and Rare Diseases Research 2(1): 11-17, 2013

New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-driven tumors. American Journal of Clinical Pathology 117(2): 183-185, 2002

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007

Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology 6(3): 115-127, 2014

Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports 9(3): 165-169, 2007

Advances in adjuvant therapy of gastrointestinal stromal tumors. Current Oncology Reports 14(4): 327-332, 2012

Latest advances in adult gastrointestinal stromal tumors. Future Oncology 13(24): 2183-2193, 2017

Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology 30(10): 1213-1220, 1999

Cytomorphology of gastrointestinal stromal tumors and extra-gastrointestinal stromal tumors: A comprehensive morphologic study. Journal of Cytology 30(1): 8-12, 2013

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Investigational New Drugs 30(6): 2377-2383, 2013

Gastrointestinal stromal tumors: diagnostic challenges and practical approach to differential diagnosis. Advances in Anatomic Pathology 14(4): 261-285, 2007

Gastrointestinal stromal tumors and proliferating cell nuclear antigen. Prognostic challenges. American Journal of Clinical Pathology 100(4): 369-370, 1993

Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors. Clinical Medicine Insights. Oncology 5: 365-379, 2011